Carotid stenting

CES 2021 Mission for the human race, Pulxion's early detection technology is here to save lives

Retrieved on: 
Thursday, January 14, 2021
Angiology, Medical specialties, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Stroke, Carotid ultrasonography, Carotid stenting

Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxion's first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the team's research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

CES 2021 Mission for the Human Race, Pulxion’s Early Detection Technology Is Here to Save Lives.

Retrieved on: 
Thursday, January 14, 2021
Health, Technology, Hospitals, Other Health, Telecommunications, Mobile, Wireless, Software, Medical specialties, Angiology, Cardiovascular system, Vascular diseases, Carotid artery stenosis, Stroke, Neurosurgery, Vascular surgery, Stenosis, Common carotid artery, Carotid ultrasonography, Carotid stenting

Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.

Key Points: 
  • Pulxions first product, PulStroke, is a novel fast-screening device for carotid artery stenosis, an early indicator of stroke.
  • Current clinical diagnosis procedures for early detection of carotid artery stenosis risk use Doppler ultrasound.
  • Therefore, patients without existing conditions are less willing to go through the assessment and thus lose the chance for early assessment and prevention.
  • These resources are accelerating the teams research and knowledge, and the company will be featured as a top-100 Taiwanese startup at CES 2021.

InspireMD Announces Renowned Interventional Cardiologist Gary S. Roubin, M.D., Ph.D., to Join Board of Directors

Retrieved on: 
Tuesday, October 13, 2020
Medical specialties, Health, Medicine, Clinical research, Clinical trial, Design of experiments, Pharmaceutical industry, Carotid stenting

Dr. Gary Roubin is an internationally renowned interventional cardiologist recognized for his pioneering work in carotid stenting and embolic and protection devices.

Key Points: 
  • Dr. Gary Roubin is an internationally renowned interventional cardiologist recognized for his pioneering work in carotid stenting and embolic and protection devices.
  • Multiple clinical studies outside the U.S. and extensive clinical practice experience have demonstrated superior outcomes compared to currently available technology.
  • Im honored to join InspireMDs Board of Directors, as the Company now has the opportunity to expand globally.
  • On behalf of the Board of Directors, we welcome Dr. Roubin and look forward to his active participation in our Company.

InspireMD, Inc. Appoints Patrick Jamnik as Vice President of Business Development and Strategic Initiatives and Reports Inducement Grants Under NYSE American Company Guide §711(a)

Retrieved on: 
Tuesday, October 6, 2020
Neurosurgery, Vascular surgery, Carotid stenting, Jamnik, Carotid artery

CGuard EPS presents the opportunity to create such an impact on the advancement of carotid artery stenting, said Mr. Jamnik.

Key Points: 
  • CGuard EPS presents the opportunity to create such an impact on the advancement of carotid artery stenting, said Mr. Jamnik.
  • Mr. Jamnik brings with him more than 15 years of global market development experience in broad-based roles with both large and emerging medical technology companies.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

Global Embolic Protection Devices Market (2020 to 2025) - Outlook and Forecast - ResearchAndMarkets.com

Retrieved on: 
Tuesday, October 6, 2020
Medical devices, Health, Carotid stenting, Neurosurgery, Vascular surgery, Stroke

The "Embolic Protection Devices Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Embolic Protection Devices Market - Global Outlook and Forecast 2020-2025" report has been added to ResearchAndMarkets.com's offering.
  • Several factors influence the growth of the global embolic protection devices market.
  • Growing demand for cerebral protection while performing neurovascular surgeries such as carotid artery stenting is another driving factor for the global embolic protection devices market.
  • The following factors are likely to contribute to the growth of the embolic protection devices market during the forecast period:
    The study considers the present scenario of the embolic protection devices market and its market dynamics for the period 2019-2025.

Embolic Protection Devices Market - Global Outlook and Forecast 2020-2025

Retrieved on: 
Thursday, October 1, 2020
Carotid stenting, Neurosurgery, Vascular surgery, Market research, Stroke

Several factors influence the growth of the global embolic protection devices market.

Key Points: 
  • Several factors influence the growth of the global embolic protection devices market.
  • Growing demand for cerebral protection while performing neurovascular surgeries such as carotid artery stenting is another driving factor for the global embolic protection devices market.
  • The following factors are likely to contribute to the growth of the embolic protection devices market during the forecast period:
    The study considers the present scenario of the embolic protection devices market and its market dynamics for the period 2019?2025.
  • The global embolic protection devices market research report includes a detailed segmentation by product, application, indication, end-user, and geography.

InspireMD to Present at the LD Micro 500 Virtual Conference on September 3, 2020

Retrieved on: 
Tuesday, August 25, 2020
Neurosurgery, Vascular surgery, Carotid stenting, Stroke, Micronet

In addition, Mr. Slosman will be available for virtual one-on-one meetings from September 1-4, 2020.

Key Points: 
  • In addition, Mr. Slosman will be available for virtual one-on-one meetings from September 1-4, 2020.
  • InspireMD seeks to utilize its proprietary MicroNet technology to make its products the industry standard for carotid stenting by providing outstanding acute results and durable stroke free long-term outcomes.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.
  • The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.

ROADSTER 2 Data Publication in Stroke Demonstrates Compelling Patient Outcomes and Strong Safety Profile with TCAR

Medical specialties, TCAR, Angiology, Cardiovascular system, Carotid artery stenosis, RTT, Stroke, Neurosurgery, Vascular surgery, Carotid stenting

The article, Early Outcomes in the ROADSTER 2 Study of TransCarotid Artery Revascularization (TCAR) in Patients with Significant Carotid Artery Disease demonstrates compelling patient outcomes with low stroke and combined stroke and death rates when utilizing TCAR.

Key Points: 
  • The article, Early Outcomes in the ROADSTER 2 Study of TransCarotid Artery Revascularization (TCAR) in Patients with Significant Carotid Artery Disease demonstrates compelling patient outcomes with low stroke and combined stroke and death rates when utilizing TCAR.
  • The publication of the ROADSTER 2 data in Stroke provides further validation of the work we are doing to improve patient safety and deliver strong clinical outcomes.
  • We are honored that ROADSTER 2 was included in this prestigious, widely read, peer reviewed journal as we continue our mission to broaden TCAR adoption.
  • The ROADSTER 2 data show stroke and combined stroke and death rates comparable to CEA in 692 high surgical risk patients enrolled in the FDA analysis population, across 43 sites.

InspireMD Gains Registration Clearance of its CGuard™ Embolic Prevention System (EPS) in Brazil

Retrieved on: 
Thursday, July 23, 2020
Medical specialties, Angiology, Cardiovascular system, Interventional radiology, Vascular diseases, Carotid artery, Stent, Common carotid artery, Artery disease, Carotid stenting

Regulatory approval of CGuard EPS in Brazil reflects not only the ANVISA'S recognition of CGuards differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease.

Key Points: 
  • Regulatory approval of CGuard EPS in Brazil reflects not only the ANVISA'S recognition of CGuards differentiating features versus conventional carotid stents, but also the need for safer treatments for carotid artery disease.
  • Brazil ranks as the sixthlargest populated country in world and the largest healthcare market in Latin America.
  • With a population over 213 million, Brazil represents an important step toward expanding commercial availability of InspireMD products into new territories.
  • Investors and security holders are urged to read these documents free of charge on the SECs web site at http://www.sec.gov.

AngioSoma Focusing on Development of Coating for Metal Stents

Retrieved on: 
Wednesday, May 27, 2020
Medical specialties, Medicine, Clinical medicine, Neurosurgery, Vascular surgery, Cardiology, Medical devices, Interventional radiology, Carotid stenting, Restenosis, Stent, Carotid endarterectomy

Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.

Key Points: 
  • Houston, TX, May 27, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- AngioSoma, Inc. ( OTC : SOAN)(AngioSoma or the Company) is pleased to announce that the Company is focusing on development and commercialization of our coating for metal stents.
  • Our coating is a biodegradable, resorbable and hemocompatible surface substrate coating for metal stents to provide embolic protection in stenting procedures.
  • We believe our coating for stents has increased potential over and above what is on the market now to block restenosis (recurrence of narrowing).
  • We consider the addressable market for stents includes not only carotid artery stenting patients but also individuals undergoing carotid endarterectomy.